ERIPAP-10 – Propranolol Hydrochloride 10mg Tablets
Propranolol is classed as a cardiovascular drug, but at 10mg it is largely prescribed by psychiatrists and neurologists. The reason is structural: Propranolol is lipophilic and crosses the blood-brain barrier, which cardioselective beta blockers such as atenolol and metoprolol do not do to the same degree. That single property is why the molecule retains a place in anxiety, tremor and migraine prophylaxis that newer, more cardioselective agents have not displaced.
Product Specifications
Brand Name: ERIPAP-10
Composition: Propranolol Hydrochloride 10 mg
Dosage Form: Tablet
Therapeutic Category: Neuropsychiatry, CNS, Cardiovascular
Manufacturing: WHO-GMP certified facility
Prescription Status: Schedule H
Storage: Store below 25°C, protect from light and moisture
Composition
Propranolol Hydrochloride — 10 mg — Non-selective beta-adrenergic receptor antagonist; lipophilic, crosses the blood-brain barrier
Mechanism of Action
Propranolol blocks both beta-1 and beta-2 adrenergic receptors without selectivity. Peripherally, beta-1 blockade reduces heart rate, contractility and cardiac output, while the same action at the peripheral level dampens the physical expression of adrenergic arousal — palpitations, tremor and the somatic symptoms that accompany acute anxiety. This peripheral effect is why the molecule is useful in situational anxiety without acting as a sedative or carrying a dependence profile.
Its lipophilicity allows central nervous system penetration, which distinguishes it from cardioselective, more hydrophilic beta blockers and underlies its established role in migraine prophylaxis and essential tremor. At 10mg, the dose sits at the low end of the range, used where the objective is symptomatic control or initiation of therapy rather than substantial cardiovascular effect.
Clinical Applications
- Situational and performance anxiety, particularly where somatic symptoms predominate
- Essential tremor
- Migraine prophylaxis
- Akathisia and antipsychotic-induced tremor
- Adjunct in thyrotoxicosis for symptomatic control
- Hypertension and angina, as part of a titrated regimen
- Certain arrhythmias, as prescribed
Why the 10mg Strength Matters
Beta blockade produces dose-dependent effects on heart rate and blood pressure, so the ability to start low and titrate is clinically significant — particularly in younger patients treated for anxiety or tremor rather than a cardiac indication, in whom baseline blood pressure is normal and unnecessary reduction is undesirable. The 10mg strength allows initiation and fine adjustment that higher-strength tablets cannot provide without splitting.
Prescriber Profile
Psychiatrists form a substantial part of the prescribing base at this strength, in situational anxiety and in managing antipsychotic-induced akathisia and tremor. Neurologists prescribe it for essential tremor and migraine prophylaxis. Physicians and cardiologists account for cardiovascular indications, and endocrinologists for symptomatic control in thyrotoxicosis.
Dosage and Administration
As prescribed by a Registered Medical Practitioner, with dose determined by indication and titrated as clinically appropriate. This is a Schedule H drug — sale by retail is permitted only against the prescription of a Registered Medical Practitioner.
Safety Information
Propranolol is non-selective, which means beta-2 blockade affects bronchial smooth muscle. It is contraindicated in bronchial asthma and used with caution in chronic obstructive pulmonary disease, where bronchospasm may be precipitated. This distinction from cardioselective beta blockers is clinically important and should be established before prescribing.
Treatment must not be discontinued abruptly, particularly in patients treated for cardiovascular indications, as sudden withdrawal can precipitate rebound tachycardia, angina or arrhythmia — dose reduction should be gradual and physician-supervised. Caution is required in diabetes, since beta blockade can mask the adrenergic warning signs of hypoglycaemia. Contraindicated in significant bradycardia, second or third degree heart block, and decompensated cardiac failure. Store below 25°C, protect from light and moisture. Keep out of reach of children.
Range Positioning
ERIPAP-10 sits at the intersection of the neuropsychiatry and cardiovascular ranges, and in practice moves through the neuropsychiatry channel. For a field team already calling on psychiatrists and neurologists, it requires no new prescriber base — it addresses akathisia, tremor and situational anxiety within calls already being made, alongside the antidepressant and antiepileptic range.
PCD Pharma Franchise Availability
ERIPAP-10 is available across India for PCD Pharma Franchise association, with territory rights allotted on a monopoly basis subject to availability. Associates receive promotional inputs and product literature across the neuropsychiatry and CNS range. Trade enquiries may be directed to Eridanus Healthcare.
Frequently Asked Questions
Why is Propranolol used in anxiety when it is a cardiovascular drug?
Propranolol blocks the peripheral adrenergic response that produces palpitations, tremor and other somatic symptoms of acute anxiety. It addresses the physical expression rather than acting as a sedative, and carries no dependence profile.
How does Propranolol differ from atenolol or metoprolol?
Propranolol is non-selective, blocking both beta-1 and beta-2 receptors, and is lipophilic enough to cross the blood-brain barrier. Cardioselective agents are more beta-1 specific and penetrate the central nervous system less, which is why they are not equivalent in tremor or migraine prophylaxis.
Why can Propranolol not be used in asthma?
Beta-2 blockade affects bronchial smooth muscle and may precipitate bronchospasm, making it contraindicated in bronchial asthma and requiring caution in COPD.
Can Propranolol be stopped abruptly?
No. Abrupt withdrawal can precipitate rebound tachycardia, angina or arrhythmia, particularly in cardiovascular indications. Dose reduction should be gradual and physician-supervised.
Why stock the 10mg strength specifically?
It is the initiation and low-dose strength, used where symptomatic control is the objective rather than substantial cardiovascular effect — the situation in most psychiatric and neurological prescribing of this molecule.
Which prescribers form the primary target base?
Psychiatrists and neurologists account for a substantial share of prescribing at this strength, with physicians, cardiologists and endocrinologists as additional coverage — relevant when building a neuropsychiatry and CNS portfolio through PCD Pharma Franchise association.
Why does this product suit an existing neuropsychiatry range?
It requires no new prescriber base. Akathisia, tremor and situational anxiety fall within calls a neuropsychiatry field team is already making, so it extends the range without extending the coverage burden.
How may a distributor enquire about territory rights?
Distributors and pharmaceutical professionals holding a valid Drug Licence and GST registration may contact Eridanus Healthcare to discuss availability and terms.
This page is intended for pharmaceutical distributors, wholesalers, and healthcare professionals. Product information is provided for commercial and educational reference and is not a substitute for professional medical advice. Eridanus Healthcare does not sell directly to patients. This is a Schedule H drug — to be sold by retail only on the prescription of a Registered Medical Practitioner. All trade enquiries are subject to valid Drug Licence and GST verification.